InvestorsHub Logo
Followers 144
Posts 8676
Boards Moderated 0
Alias Born 10/07/2013

Re: eightisenough post# 288702

Thursday, 07/30/2020 9:00:20 AM

Thursday, July 30, 2020 9:00:20 AM

Post# of 426560
e-

You're insulting the board's intelligence ... Lawsuit should not have been lost period

You are definitely clever, more intelligent than me because I could not imagine why anybody tells to Judge Du (before the order):

- Please be aware, the USPTO did not cite Kurabayashi but considered it ... dive a deference to the USPTO, take unexpected benefit as existing, valid
- Please do not weight the existing and non-existing secondary consideration against each others, the existing matter only

I am sure if you were you would tell these ...

if jt replaced, sp would jump to $8-9.

or go below $5-6 ... WS is not about emotion and a replacement now is not a good sign.

sp is CONSISTENTLY down b/c ws lost confidence. If it was JUST b/c appeal we wouldn't be going down and not 6.4.

You are mixing confidence and count / built-in uncertainty. The pps is CONSISTENTLY down b/c no settlement was announced and WS "emphasized" "that the courts can be unpredictable in such matters".

WS knows jt will gia in eu--that is the problem

and you know what WS knows ... The Co will decide EU (GIA / not likely or licensing / revenue share or out-license / sell the rights) based on numbers, not on emotion. btw: do not be surprised if no EU announcement before CAFC ruling (if a real BO interest exist).

"any CEO hired Cov. should be fired"--if trial is lost! The point is if you lose you must be held responsible--the same way when you win you get the credit.

They did not lose ... DC ruled against them but the appeal is ongoing. If they will win (CAFC overturn DC), how will you see / take it? DC ruling was their fault or Du's?

Best,
G

Disclosure: I wrote this post myself, and it expresses my own opinions (IMHO). I am not receiving compensation for it.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News